The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyps

Targeted monoclonal antibodies (dupilumab, omalizumab, mepolizumab, benralizumab) for severe type-2 inflammation CRSwNP refractory to corticosteroids and surgery, transforming long-term disease control.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our KBB (Kulak Burun Boğaz) department. Book Appointment →

What is Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyps?

CRSwNP affects 1-4% of the population and 25-30% of chronic rhinosinusitis patients. Pathogenesis involves type-2 inflammation: epithelial alarmins (TSLP, IL-25, IL-33) activate ILC2 and Th2 cells, driving IL-4/IL-5/IL-13 release, eosinophilic infiltration, polyp formation, and tissue remodeling.

Severe CRSwNP is defined by uncontrolled symptoms despite optimal medical therapy and prior endoscopic sinus surgery (≥1 surgery), with significant impact on quality of life (SNOT-22 >40), persistent polyp burden (NPS ≥4), olfactory dysfunction, and frequent oral steroid courses or comorbid severe asthma.

Biologic eligibility (EUFOREA/EPOS 2020 criteria): T2 inflammation evidence (blood eosinophils ≥250 cells/μL, total IgE elevated, tissue eosinophilia), failure of standard medical-surgical management, severe symptoms with QoL impact. Treatment selection considers comorbidities: dupilumab for asthma, omalizumab for elevated IgE/allergic asthma, mepolizumab/benralizumab for eosinophilic asthma.

Symptoms

Persistent nasal obstruction unresponsive to topical steroids
Severe hyposmia or anosmia (often the most distressing symptom)
Recurrent polyp regrowth after sinus surgery (≥1 surgery)
Need for repeated oral corticosteroid courses (≥2 per year)
Comorbid severe asthma, NSAID-exacerbated respiratory disease
High SNOT-22 score (>40) and reduced quality of life
Facial pressure, nasal discharge, postnasal drip

Risk Factors

Type-2 inflammatory phenotype (eosinophilia, elevated IgE, IL-5)
Comorbid asthma (40-60% of CRSwNP), allergic rhinitis
Aspirin/NSAID-exacerbated respiratory disease (Samter's triad)
Prior failed endoscopic sinus surgery with polyp recurrence
Cystic fibrosis (CRSwNP variant)
Female sex (slight predilection in some studies)
Genetic predisposition (HLA, filaggrin polymorphisms)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent nasal polyps despite intranasal corticosteroids and oral steroid courses
  • Recurrence after endoscopic sinus surgery requiring revision consideration
  • Severe smell loss impacting quality of life
  • Comorbid severe asthma not controlled with standard therapy
  • Allergy/immunology and rhinology multidisciplinary referral for biologic candidacy

Treatment Methods

01
Dupilumab (anti-IL-4Rα): SC 300 mg every 2 weeks; pivotal SINUS-24/52 trials showed significant reduction in polyp score, SNOT-22, smell scores, and oral steroid use. First-line in many guidelines, particularly with comorbid asthma or atopic dermatitis
02
Omalizumab (anti-IgE): SC dosing per weight and total IgE level (75-600 mg every 2-4 weeks); POLYP-1/2 trials showed polyp reduction and symptom improvement; prefer with allergic asthma, elevated IgE 30-1500 IU/mL
03
Mepolizumab (anti-IL-5): SC 100 mg every 4 weeks; SYNAPSE trial demonstrated polyp reduction and decreased surgery need; preferred with eosinophilic asthma
04
Benralizumab (anti-IL-5Rα): SC 30 mg every 4 weeks then every 8 weeks; depletes eosinophils via ADCC; OSTRO trial showed polyp and symptom improvement
05
Patient selection algorithm: dominant phenotype-based (allergic-asthma → omalizumab; eosinophilic-asthma → mepolizumab/benralizumab; mixed-allergic-eosinophilic → dupilumab)
06
Treatment monitoring: NPS (Nasal Polyp Score 0-8), SNOT-22, UPSIT smell test, peripheral eosinophil count (caution: dupilumab causes transient eosinophilia 5-10%), polyp endoscopy at 6 months
07
Continued standard therapy: high-volume nasal saline irrigation with budesonide, ongoing intranasal corticosteroid sprays (mometasone, fluticasone), allergic comorbidity management
08
Treatment duration: indefinite while effective; trial discontinuation studies suggest most patients relapse, supporting long-term therapy
09
Combination with surgery: appropriately-timed endoscopic sinus surgery before biologic may improve drug delivery (functional sinus cavity); some patients avoid revision surgery on biologics
10
Adverse events: dupilumab — eosinophilia, conjunctivitis (5-10%), injection site reactions; omalizumab — anaphylaxis (rare); IL-5 — reduced eosinophil count, injection reactions; safety profile generally favorable
11
Cost-effectiveness considerations: biologics are expensive; insurance prior authorization typically requires documented severe disease, prior surgery, and refractoriness; emerging real-world evidence supports cost-effectiveness in severe CRSwNP
12
Pediatric extension: dupilumab approved for adolescents (≥6 years for asthma, ≥18 for CRSwNP currently); pediatric CRSwNP biologic trials ongoing

Which Department to Visit?

You can visit our KBB (Kulak Burun Boğaz) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About KBB (Kulak Burun Boğaz) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.